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Abstract
Background: In clinical research, obtaining informed consent from participants is an ethical and legal requirement.
Conveying the information concerning the study can be done using multiple methods yet this step commonly
relies exclusively on the informed consent form alone. While this is legal, it does not ensure the participant’s true
comprehension. New effective methods of conveying consent information should be tested. In this study we
compared the effect of different methods on the knowledge of caregivers of participants of a clinical trial on
Pemba Island, Tanzania.
Methods: A total of 254 caregivers were assigned to receive (i) a pamphlet (n = 63), (ii) an oral information session
(n = 62) or (iii) a pamphlet and an oral information session (n = 64) about the clinical trial procedures, their rights,
benefits and potential risks. Their post-intervention knowledge was assessed using a questionnaire. One group of
caregivers had not received any information when they were interviewed (n = 65).
Results: In contrast to the pamphlet, attending an information session significantly increased caregivers’ knowledge
for some of the questions. Most of these questions were either related to the parasite (hookworm) or to the trial
design (study procedures).
Conclusions: In conclusion, within our trial on Pemba Island, a pamphlet was found to not be a good form of
conveying clinical trial information while an oral information session improved knowledge. Not all caregivers
attending an information session responded correctly to all questions; therefore, better forms of
communicating information need to be found to achieve a truly informed consent.
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Background
Informed consent is an essential ethical and legal re-
quirement in research involving human subjects [1].
Nowadays, it is expected that clinical trials adhere to
the International Conference on Harmonisation Good
Clinical Practice (ICH GCP) guidelines [2]. These
guidelines define informed consent as “a process by
which a subject voluntarily confirms his or her will-
ingness to participate in a particular trial, after having
been informed of all aspects of the trial that are rele-
vant to the subject’s decision to participate” and the
9th principal of ICH GCP is that “freely given in-
formed consent should be obtained from every sub-
ject prior to clinical trial participation” [2].
Proof of obtaining informed consent is documented
using a written, signed and dated informed consent form
(ICF) [2]. Informed consent is a procedure through
which subjects, after having received the entire content
and procedures of the clinical trial, can voluntarily pro-
vide willingness for participation; it is the investigator’s
responsibility to ensure that the consent process is con-
ducted appropriately [2, 3]. Although the GCP guidelines
provide a list of topics which should be presented both
in the informed consent discussion and in the ICF, they
do not give any advice on how to provide this informa-
tion. Different methods and educational materials can be
used to properly inform subjects, but the selection of the
techniques is entirely in the hands of the researchers
themselves, leaving room for uninformed decisions or
even misconduct. Many trials still rely on lengthy and
complex ICFs alone to transfer all relevant information
to participants [4]. For decades it has been emphasized
that the traditional ICF, in most cases, is not a suffi-
ciently good method of conveying information since
often participants do not read the ICF [5] or fail to
understand after reading it [6, 7]. The fact that many in-
vestigators view ICFs as mere legal proof of a partici-
pant’s agreement has increased their complexity, and
consequently reduced the participant’s ability to under-
stand its content. This results in an informed consent
process, which is legally correct, but does not guarantee
the participant’s true comprehension of the study [8].
People often confuse receiving medical care with partici-
pating in a clinical trial [9, 10], or do not understand
concepts such as randomization, the right to withdraw
at any time, and the risks and benefits of participation
[11]. More visual, interactive and engaging forms of con-
veying information are required where an ICF does not
truly inform.
Additionally, in practice, researchers usually do not
know to what extent individuals have understood the
aim, procedures, their rights, benefits and potential risks
of a clinical trial when they agree to participate [12, 13].
This issue is particularly alarming in low- and middle-
income countries where a combination of low educa-
tional levels, poor access to health care and low health
literacy levels increase the risk of uninformed consent-
ing. Indeed, it has been shown that participants in low-
and middle-income countries are less likely to refuse to
participate in clinical research as well as withdraw from
it when compared to participants in developed countries
[1, 14]. Moreover, the information which a subject uses
to decide whether or not to participate in a clinical trial,
is often communicated inappropriately in limited-
resource settings [8].
The present study aimed at assessing whether diverse
forms of delivering the same informed consent informa-
tion generated different levels of understanding in care-
givers of clinical trial participants receiving two
anthelminthic treatment regimens on Pemba Island,
Tanzania. Using a short questionnaire, we compared the
clinical trial-related knowledge of caregivers assigned to
groups with different forms of providing information: (i)
pamphlet only, (ii) oral information session only, and
(iii) pamphlet plus oral information session. A forth
group of caregivers served as control and did not receive
any information other than the ICF before the interview
(an information session was conducted after completion
of questionnaire).
Methods
Study design, ethics and participants
The study was embedded in a school-based, randomized,
double-blinded clinical trial conducted at Piki Primary
School, on Pemba Island, Tanzania, from July to Sep-
tember 2017. The primary objective of the trial was to
evaluate the safety and efficacy of a multiple dose
mebendazole regimen (3 days 100 mg bid) versus a single
dose of 500 mg mebendazole against hookworm infec-
tions in 186 children aged 6 to 12 years. The method-
ology and details of this clinical trial (number
NCT03245398, ClinicalTrials.gov) have been published
elsewhere [15]. Caregivers, who allowed the participation
of their child, were asked to sign a written informed
consent. Illiterate caregivers provided a thumbprint
while an impartial witness signed to verify that all infor-
mation in the informed consent form was conveyed
correctly.
Information session and pamphlet
All children invited to participate in the clinical trial
were orally informed about the date and time of the in-
formation session, which one of their caregivers should
attend. Children were given an ICF, which they should
hand over to their caregiver before the information ses-
sion. The information session covered all important
topics included in the ICF in the most simple and clear
language possible. The content and language of the
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speech were discussed together with the local research
staff and were standardized (see Additional file 1). Care-
givers were encouraged to ask any questions they may
have before deciding whether their child should partici-
pate in the trial or not.
Upon the announcement of the date and time of the
information session, the research staff handed out to half
the children a pamphlet addressed to their caregivers,
which was developed and adapted to the local culture
and conditions by the research team and local staff
(Additional file 2). Figure 1 describes the study flow in
each of the caregiver groups.
The key messages of the information session and the
pamphlet were the same and included the following in-
formation: (i) hookworm is a parasite, which infects us
through the skin when we walk barefoot; (ii) hookworm
can cause a child to not develop properly and have diffi-
culties at school; (iii) one can treat hookworm with a
specific medication; (iv) in this study we intend to find
the “best amount” of mebendazole to cure their child;
(v) mebendazole can cause mild adverse events; (vi) the
caregiver should be the one deciding whether the child
participates or not; (vii) if the child remains infected
with hookworm after treatment he/she will receive an-
other drug (tablet); (viii) the child can withdraw from
the study at any time, with no consequence and would
still receive treatment; (ix) the treatment is free, nobody
is paid to participate but all caregivers would be reim-
bursed USD 2 to cover their transport to the informa-
tion session; (x) only the child’s caregivers and research
staff will have access to his/her personal information;
(xi) to participate each child will have to provide several
stool samples and a small blood sample but no urine
sample; and (xii) children should inform the study team
about how he/she is feeling after treatment and allow a
doctor to check his/her overall health.
Questionnaire and data collection
Data were collected using a questionnaire consisting of
ten multiple choice questions (each with four choices)
and seven true or false questions (Table 1, Add-
itional file 3). The questionnaire was orally administered
in Swahili by six trained interviewers. Only one caregiver
per child was interviewed. Caregivers who had more
than one child invited to participate in the trial were
only interviewed once. After being interviewed, care-
givers in the control group attended an information ses-
sion before they were invited to sign the ICF. Caregivers
who chose not to sign the ICF for their child to partici-
pate in the clinical trial but still agreed to respond to the
questionnaire were included in this study. Interviewers
visually estimated the caregivers’ age and recorded it.
Children of caregivers participating in this survey also
responded to several socioeconomic questions inquiring
about possession of specific household assets (soap,
radio, television, computer, cell phone, fridge, fan, bike,
scooter, car, tractor, electricity) and household condi-
tions (source of drinking water, type of roof, walls and
floor).
Initially, the questionnaire was developed in English by
the authors. A meeting including the five local inter-
viewers with the aim of adapting the questionnaire to the
local culture and educational level resulted in several
changes to the questionnaire. The final questionnaire was
translated to Kiswahili. Interviewers underwent three days
of training about the trial and how to administer the ques-
tionnaire. Questionnaires were administered in the same
classroom where the information session took place and
each interview lasted about 15min.
Treatment allocation
The assignment of caregivers into one of four groups
was accomplished in two steps: first, they were divided
Fig. 1 Flow diagram of the order of procedures in each of the four groups of caregivers
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into receiving the pamphlet (their child/children took
the pamphlet home) or not, and second they were di-
vided into receiving the information session before or
after answering the questionnaire (Fig. 1). The day be-
fore the start of the information sessions we randomly
assigned 400 children to receive the pamphlet or not.
However, of the caregivers who showed up for an infor-
mation session, the number of children who were found
Table 1 List of multiple choice and true/false questions. Correct
multiple choice answers are highlighted with an arrow and
true/false questions are marked with T (true) or F (false)
Multiple choice questions
1. What is hookworm?
A A worm that can infect us if we drink dirty water.
→ B A worm that can go into our feet if we walk barefoot.
C A worm that can infect us if we eat rotten food.
D A worm that can get to our food through flies.
E Don’t know.
2. Why is hookworm bad for your child?
A My child will get pimples all over the body.
B My child’s urine will become red (blood).
→ C My child may not grow well and may have difficulties at school.
D My child will be very hungry all the time.
e Don’t know.
3. Is it possible to treat hookworm?
a No, it is not possible to treat hookworm.
b Yes, it is possible to treat if my child eats a lot of healthy food
like veg/fruit.
c Yes, I should take my child to the traditional healer.
→ d Yes, my child can receive medication that will kill the hookworm.
e Don’t know.
4. What do we want to do in this study?
a To see if mebendazole kills the worms in my child’s belly
because this drug has never been used before.
b To see if mebendazole kills the worms that are in my child’s
feet.
c We want to see if mebendazole is better than another drug
called albendazole at killing the worms.
→ d We want to find out what is the best amount of a mebendazole
to kill the hookworm in my child’s belly.
e Don’t know.
5. Who should decide if your child should participate in this study?
a Teacher
→ b Mother/father
c Doctors or nurses
d Neighbor or relative
e Don’t know.
6. What happens if your child still has worms after the treatment?
a There is nothing that we can do
b We will give him/her an injection to kill the worms
c Your child should drink a lot of water
→ d We will give him/her another pill to kill the worms
e Don’t know.
7. Can your child give up participating during the study?
→ a Yes, my child can give up and there is no consequence. He/she
will still receive treatment.
b Yes, but my child will not receive treatment.
Table 1 List of multiple choice and true/false questions. Correct
multiple choice answers are highlighted with an arrow and
true/false questions are marked with T (true) or F (false)
(Continued)
Multiple choice questions
c No, my child cannot give up if I decide he participates he/she
has to stay until the end of the study.
d Only if the doctor and teacher agree that he/she can give up.
e Don’t know.
8. What about payment?
a There are some costs for you: you will have to pay for your
child’s treatment.
→ b There are no costs for you: the treatment is free and you will
get 2$ if you came to the information session.
c You will receive money if your child accepts the treatment
d You will only get money if the treatment kills the worms
e Don’t know.
9. Is the treatment we will give to your child (mebendazole) safe?
a Nothing bad can happen if my child takes the treatment.
b If my child takes the treatment he/she will not be able to walk
for a few days.
→ c If my child takes the treatment, he/she may feel some things
like a belly ache or a headache but nothing very dangerous.
d If my child takes the treatment he will sleep all day.
e Don’t know.
10. Who will be able to see your child’s personal information?
a Neighbors
→ b Only study investigators
c Teacher
d Only you
e Don’t know.
True or false questions
11. What does your child need to do if he/she participates in this study?
Will he have to …
T a Give us several stool samples?
F b Pay for the medication to kill the worms (mebendazole)?
T c Tell us if he/she is feeling well after the medication?
F d Give us a urine sample?
F e Only give us one stool sample?
T f Give us a small blood sample?
T g Accept that a doctor checks his/her health?
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infected with hookworm were not sufficient for our clin-
ical trial. To reach our target sample size (180 children
with hookworm infections) we handed out more pam-
phlets and invited more caregivers for information ses-
sions. In this second round of pamphlet distribution we
used an alternate distribution (every other child received
a pamphlet). The information session and interviews
were held on the same day. On the day of an informa-
tion session, those caregivers arriving early were imme-
diately interviewed creating the control and pamphlet
only groups. Caregivers arriving later attended the infor-
mation session before being interviewed forming the in-
formation session only and the information session plus
pamphlet groups. Not all caregivers of participating chil-
dren responded to the questionnaire due to time con-
straints. Regardless of which group they belonged to, all
caregivers attended an oral information session before
being invited to sign the ICF.
Sample size
This study was embedded in a clinical trial for which a
minimum of 79 participants were required per treatment
arm. Accounting for a loss to follow-up of 12%, the sample
size of the clinical trial was 180 participants (90 per arm).
In order to reach this sample size, 364 children were con-
sented and screened for hookworm infections. Due to time
restrictions, not all caregivers who attended an information
session and provided consent could be interviewed. A mean
of 62 participants per group were included in this study. In
the control group, caregivers were assumed to have a 25%
chance of answering correctly each of the multiple choice
questions. Our sample size would enable the detection of a
20% increase in correctly answered question (from 25 to
45%) to be detected with 80% power.
Statistical analysis
All caregivers who responded to the questionnaire were
included in the analysis. The effects of the pamphlet and
information session on the proportion of each question
that was correctly answered were estimated using a lo-
gistic regression model adjusting for interviewer, care-
giver’s age and asset index. We adjusted the p-values for
multiple comparisons using the Benjamini-Hochberg
procedure; this was done separately for pamphlet and in-
formation session [16]. Additionally, we summarize bin-
ary data using proportions.
We took into account the clustering of children within
classes using a random effect. An interaction between
the effects of pamphlet and information session was
tested and no evidence of a synergistic effect for any of
the questions was found resulting in removal of the
interaction from the model.
The caregivers’ age was split into three categories: ≤
25, 26 to 50, and ≥ 51 years. An asset index was used as
a proxy of socioeconomic status. This index was gener-
ated by summing the number of assets owned by the
child’s household [17]. Children with incomplete ques-
tionnaires (n = 5) could not be attributed an asset score.
Results
A total of 254 caregivers responded to the questionnaire
over 12 information sessions: 65 in the control group, 63
in the pamphlet only group, 62 in the information ses-
sion only group, and 64 in the pamphlet plus informa-
tion session group (Fig. 1).
Asset ownership information was obtained for 249
participants. Children reported to drink water from dif-
ferent water sources: from a well (92%), from a tap (7%),
or both (1%). Only 40% of children reported to have
electricity. The remaining results on asset possession are
presented as an Additional file (see Additional file 4).
The pamphlet did not significantly increase caregivers’
understanding. Even though most parents assigned to
receive the pamphlet reported to have indeed received it
(77%, average of both groups) and read it (80% of the 97
caregivers who received it), many said they did not
understand it well (Table 2). Caregivers who had more
than one child were assigned to more than one caregiver
group, meaning some caregivers who should not have
received the pamphlet did receive it. It is important to
note that literacy levels were not assessed.
The proportion of caregivers responding correctly to
the 17 questions varied depending on the question and
group, ranging from 25 to 100% (Table 3). There was no
evidence of an increase in providing correct answers
with the pamphlet. However, caregivers who had
attended an information session before responding to
the questionnaire had a higher proportion of correct an-
swers for most of the 17 questions, with significant in-
creases for seven questions. Questions related to the
parasite itself and concerning the procedures of this
study were answered correctly more often in groups at-
tending an information session. The full data on care-
givers’ answers to every question are presented in
Additional file 5.
Discussion
Any study including human subjects should properly in-
form participants before obtaining informed consent. To
date, few studies have investigated to what extent partic-
ipants truly comprehend all the information before sign-
ing the ICF. Additionally, since it has been shown that
an ICF alone is not sufficiently good at conveying infor-
mation, new methods to do so are needed. Our study
aimed at testing different interventions (pamphlet alone,
information session alone or both) and measuring their
impact on the caregivers of participants’ knowledge. We
found that the information session had a positive impact
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on caregivers’ understanding of the clinical trial, but re-
ceiving a pamphlet did not.
The lack of effect of the pamphlet on the caregivers’
understanding could be related to the fact that although
the majority of caregivers received and read it, they did
not understand it. Also, caregivers in the pamphlet only
group did not have the opportunity to ask questions be-
fore being interviewed, unlike the other two intervention
groups. Finally, caregivers meant to receive the pamphlet
may have shown it to those not meant to receive it, di-
luting its effect. Hence, our finding indicates that a
pamphlet might not always be an appropriate
communication tool. The impact of a communication
tool differs among cultural settings so different methods
should be tested in different regions. In many African
settings oral communication is given more value than
written communication, most likely due to the low liter-
acy levels, particularly in adults [18]. Alternative forms
of conveying information such as slide shows, theaters,
videos and songs have been shown to be more effective
than written formats [19]. It would be useful if GCP
would provide guidance on the best ways to deliver infor-
mation during the informed consenting process since most
clinical researchers do not have formal training in social,
Table 2 Caregivers who reported receiving, reading and understanding the pamphlet
Answers Control (n = 65) Pamphlet only (n = 63) IS only (n = 62) IS + pamphlet (n = 64)
Did you receive the pamphlet? Yes 3 (5%) 50 (79%) 8 (13%) 47 (75%)
Did you read the pamphlet? Yes 2 (3%) 40 (63.5%) 4 (7%) 38 (60%)
How well did you understand it?a Not at all 0 (0%) 1 (3%) 0 (0%) 2 (5%)
Not well 1 (50%) 9 (23%) 0 (0%) 4 (11%)
More or less 1 (50%) 18 (46%) 2 (50%) 13 (35%)
Well 0 (0%) 11 (28%) 2 (50%) 18 (49%)
IS Information session; apercentage of parents who received and read the pamphlet. We are missing data on the level of understanding of two caregivers
Table 3 Number of caregivers (%) answering correctly to each of the questions and effect (p-value) of belonging to one of the two
groups which received the pamphlet or to one of the two groups which attended an information session
Caregiver group P-value
for the
effect of
pamphlet
P-value for the
effect of info
session
Control Pamphlet Info session Info session + pamphlet
Multiple choice questions
What is hookworm? 30 (46%) 33 (52%) 53 (86%) 52 (81%) 0.99 0.006
Why is it bad? 24 (37%) 26 (41%) 35 (58%) 46 (72%) 0.51 0.006
Can one be treated? 52 (80%) 54 (86%) 52 (84%) 54 (86%) 0.72 0.53
Why are we doing this study? 25 (39%) 31 (49%) 35 (58%) 34 (53%) 0.99 0.13
Who decides if your child participates? 59 (91%) 57 (91%) 60 (97%) 61 (95%) 0.99 0.27
What if your child still has hookworm? 55 (85%) 44 (71%) 50 (83%) 54 (84%) 0.51 0.53
Can you give up participating? 27 (43%) 21 (33%) 19 (31%) 23 (36%) 0.72 0.31
What about payment? 52 (81%) 47 (76%) 57 (92%) 61 (97%) 0.90 0.02
Is mebendazole safe? 25 (40%) 22 (36%) 20 (33%) 19 (30%) 0.87 0.53
Who can see your child’s information? 24 (37%) 21 (33%) 32 (53%) 30 (47%) 0.82 0.02
True or false questions (What will your child have to do if he/she participates?)
Provide several stool samples 63 (97%) 61 (97%) 62 (100%) 63 (98%) 0.72 0.76
Provide one stool sample 17 (26%) 23 (37%) 29 (47%) 24 (38%) 0.99 0.09
Provide a urine sample 16 (25%) 20 (32%) 35 (56%) 32 (50%) 0.99 0.006
Provide a small blood sample 54 (83%) 56 (89%) 60 (97%) 61 (95%) 0.72 0.02
Pay for the treatment 52 (80%) 48 (76%) 59 (95%) 57 (89%) 0.72 0.02
Tell us how he/she feels after treatment 65 (100%) 55 (87%) 60 (97%) 61 (95%) 0.51 0.53
Allow a doctor/nurse to examine him/her 63 (97%) 59 (94%) 61 (98%) 63 (98%) 0.51 0.35
The p-values refer to the estimated effect of providing a pamphlet, and of the information sessions. They were calculated using logistic regression with a random
effect for class. The effects of pamphlet and information session were assumed to be additive: there was no evidence for any interactions between pamphlet and
information session. The p-values have been adjusted for multiple comparison using the Benjamini-Hochberg procedure
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anthropological or communication sciences. These recom-
mendations should be tailored for different settings.
In contrast, having attended an information session in-
creased the proportion of correct answers given to most
questions and these increases were significant for half of
the questions. Most of these questions were either re-
lated to the parasite (hookworm) or to the trial design
(procedures). For example, compared to caregivers who
did not attend an information session, those who did
knew significantly more often that their child did not
have to provide a urine sample or pay for treatment and
that they would need to provide a small blood sample
(finger prick). Also, they were more knowledgeable con-
cerning the mode of transmission of hookworm and its
consequences on health. It is worth highlighting that in
this study we had 12 information sessions of rather small
size allowing us to increase engagement with caregivers.
To minimize any confounding due to the speaker of the
information session, the same person led every session
and its content was standardized across sessions.
However, three important facts about our clinical trial
were worryingly misunderstood by caregivers, even after
an information session. First, although about half of the
caregivers understood why we were conducting this clin-
ical trial (to find the most effective regimen of mebenda-
zole against hookworm), 30% responded it was because
this drug had never been used before. Second, 53% of
caregivers thought that their child cannot withdraw from
the study once they had accepted to participate. Lastly,
62% of parents reported that nothing bad could happen
after receiving treatment (the correct answer was that
the drug may have some mild side effects such as ab-
dominal pain or a headache). Our results are in line with
those reported in a systematic review about informed
consent comprehension in African research settings,
which documented that only approximately half of care-
givers understood the right to withdraw and the risks in-
volved [10]. Thus, our results show that, although
caregivers received these key messages during an infor-
mation session, their comprehension was low. One rea-
son could be that this format of transferring knowledge
is not the most appropriate for communicating this type
of information, particularly in a context where health lit-
eracy remains limited. Therefore, it is important to ex-
plore other formats of transmitting key messages of a
clinical trial using pictures, videos or even theaters. Pre-
vious studies have shown that, for example, the use of
videos significantly increases participants’ comprehen-
sion when compared to a standard informed consent
procedure [20–22]. Another potential explanation for
the poor understanding of caregivers might be related to
the concept of “authority of knowledge”, i.e. caregivers
may feel it is not their job to understand these issues or
judge their legitimacy, consequently leaving the decision
in the hands of people who truly know the subject.
Therefore, it is possible that caregivers choose to trust
the research staff, the teachers’ decision to support the
study, the ethics committee approving the trial and the
government allowing such studies to take place in their
communities instead of making a real effort to under-
stand themselves [23]. Further studies would be neces-
sary to better understand “how much information is too
much information?” in the context of a clinical trial in
these settings and whether caregivers indeed feel that
they do not need to truly understand the study back-
ground [24].
Additionally, some questions were answered correctly
by most caregivers, regardless of which group they
belonged to, i.e. having attended an information session
was not the reason why they responded correctly. It
seems to be known that treatment for hookworm exists,
that caregivers should be the ones deciding whether
their child participates in the trial or not, that the re-
search staff will treat children still found infected at
follow-up, that the child is asked for several stool sam-
ples during the study, that the child should let a doctor
know how he/she is feeling after treatment, and that a
child should accept a doctor’s physical examination.
Several limitations of our study are worth highlighting.
First, the randomization was not conducted in a consist-
ent manner. Although children were initially randomly
assigned to receive the pamphlet or not, insufficient
caregivers due to lack of adherence and insufficient chil-
dren infected with hookworm, led to alternating distri-
bution of the pamphlet in an attempt to balance both
groups. Second, parents were assigned to each of the
groups (with or without information session upon the
interview) depending on their time of arrival to the in-
formation session classroom. Parents arriving first were
immediately interviewed. However, parents who reached
the study site first might have been more interested in
the study and, therefore, possibly more knowledgeable.
If this was the case, there could be some bias decreasing
the effect of the information session. Third, because we
were working in a single school, we could not avoid
knowledge contamination between groups. It is likely
that caregivers who attended some of the first informa-
tion sessions talked to caregivers who had not yet
attended an information session, sharing some of their
newly acquired knowledge. This way, the effect of the in-
formation session may have become less apparent.
Moreover, it would have been interesting to study the ef-
fect of the caregivers’ gender on understanding, docu-
mented in previous studies [25, 26], but gender was not
recorded in our study. Likewise, checking for caregivers’
literacy levels would have been useful for the interpret-
ation of our particular results. Finally, it has been shown
that closed-ended questionnaires assessing knowledge
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tend to overestimate the participants’ understanding of
informed consent information. Thus, future studies
could consider including either open-ended questions or
allow for spontaneous answers to avoid influencing par-
ticipants’ responses [27].
Conclusions
Although caregivers already had some awareness on the
disease and study procedures they gained additional
knowledge during information sessions, yet not all the
important messages conveyed were truly understood.
Moreover, the study found that a pamphlet was not a
good tool to increase people’s knowledge. Therefore, to
achieve a truly informed consent of participants and/or
their caregivers, better forms of delivering information
need to be found.
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